Skip NavigationSkip to Content

Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia

  1. Author:
    Yang, Xiaohong R
    Devi, Beena C R
    Sung, Hyuna
    Guida, Jennifer
    Mucaki, Eliseos J
    Xiao, Yanzi
    Best, Ana
    Garland, Lisa
    Xie, Yi
    Hu, Nan
    Rodriguez-Herrera, Maria
    Wang, Chaoyu
    Jones, Kristine
    Luo, Wen
    Hicks, Belynda
    Tang, Tieng Swee
    Moitra, Karobi
    Rogan, Peter K
    Dean, Michael
  2. Author Address

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, NCI/NIH, Bethesda, Rockville, MD, USA. royang@mail.nih.gov., Department of Radiotherapy, Oncology and Palliative Care, Sarawak General Hospital, Kuching, Sarawak, Malaysia., Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada., Cancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Department of Biology, Trinity Washington University, Washington, DC, USA.,
    1. Year: 2017
    2. Date: Oct
    3. Epub Date: 2017 Jun 29
  1. Journal: Breast Cancer Research and Treatment
    1. 165
    2. Pages: 687-697
  2. Type of Article: Article
  1. Abstract:

    To characterize the spectrum of germline mutations in BRCA1, BRCA2, and PALB2 in population-based unselected breast cancer cases in an Asian population. Germline DNA from 467 breast cancer patients in Sarawak General Hospital, Malaysia, where 93% of the breast cancer patients in Sarawak are treated, was sequenced for the entire coding region of BRCA1; BRCA2; PALB2; Exons 6, 7, and 8 of TP53; and Exons 7 and 8 of PTEN. Pathogenic variants included known pathogenic variants in ClinVar, loss of function variants, and variants that disrupt splice site. We found 27 pathogenic variants (11 BRCA1, 10 BRCA2, 4 PALB2, and 2 TP53) in 34 patients, which gave a prevalence of germline mutations of 2.8, 3.23, and 0.86% for BRCA1, BRCA2, and PALB2, respectively. Compared to mutation non-carriers, BRCA1 mutation carriers were more likely to have an earlier age at onset, triple-negative subtype, and lower body mass index, whereas BRCA2 mutation carriers were more likely to have a positive family history. Mutation carrier cases had worse survival compared to non-carriers; however, the association was mostly driven by stage and tumor subtype. We also identified 19 variants of unknown significance, and some of them were predicted to alter splicing or transcription factor binding sites. Our data provide insight into the genetics of breast cancer in this understudied group and suggest the need for modifying genetic testing guidelines for this population with a much younger age at diagnosis and more limited resources compared with Caucasian populations.

    See More

External Sources

  1. DOI: 10.1007/s10549-017-4356-8
  2. PMID: 28664506
  3. WOS: 000411105800023

Library Notes

  1. Fiscal Year: FY2016-2017
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel